NIMI
OREX

Natixis Investment Managers International’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Natixis Investment Managers International’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,726
Closed -$213K – 491
2015
Q1 		$213K Sell
2,726
-3,773
-58% -$234K 0.03% 297
2014
Q4 		$394K Buy
6,499
+4,497
+225% +$226K 0.05% 223
2014
Q3 		$85K Hold
2,002
– – 0.01% 181
2014
Q2 		$124K Hold
2,002
– – 0.02% 189
2014
Q1 		$130K Buy
+2,002
New +$135K 0.02% 156

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Natixis Investment Managers International's OREX Position: Q2 2015 in Review

Natixis Investment Managers International sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 2,726 shares — an estimated $213K sold.

Natixis Investment Managers International first reported a position in OREX in Q1 2014 and held it in 5 quarters. The position peaked at $394K in Q4 2014. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • Natixis Investment Managers International reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Natixis Investment Managers International sold 2,726 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $213K.
  • Natixis Investment Managers International first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 5 quarters.
  • Natixis Investment Managers International's Orexigen Therapeutics, Inc. position peaked at $394K in Q4 2014.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Natixis Investment Managers International's 13F filing for Q2 2015, filed 14 Aug 2015.